Knight Therapeutics (OTCMKTS:KHTRF) Shares Up 0.4% – Here’s What Happened

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares rose 0.4% on Thursday . The stock traded as high as $6.6412 and last traded at $6.6020. 5,043 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 9,001 shares. The stock had previously closed at $6.5735.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Knight Therapeutics Price Performance

The company has a 50-day moving average price of $6.07 and a 200 day moving average price of $5.09.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.